Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Drug Safety
Novo Nordisk's chief says the Danish company is stockpiling medicines in case of "no deal" hard Brexit
Endocrinologic and Metabolic Drugs Advisory Committee will reconsider 2008 guidance on evaluating CV risks in antidiabetic therapies at two-day meeting in October.
Zhejiang Huahai has detected a second probable carcinogen in valsartan API it manufactured. Meanwhile risk analysis suggests cancer risk from the first probable carcinogen is low, at least so far.
29 Rx drug products have dermal safety study results in their labeling; workshop panelists cite need for sponsors to finalize formulations earlier.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.